Clinical trials: Heart Failure, Reduced Ejection Fraction
Atrial Fibrillation, Arrythmia
Arrythmia Burden in Cardiac Contractility Modulation (CCM)
The Impulse Dynamics Optimizer Device is a Food and Drug Administration (FDA) approved; commercially available device indicated for patients with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- ABC (NCT05704426)
- Testing
- Impulse Dynamics Optimizer Device
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hackensack Meridian Health
Heart Failure With Reduced Ejection Fraction
Dashboard Activated Services and Tele-Health for Heart Failure
The Dashboard Activated Services and tele-Health for Heart Failure (DASH-HF) study is a pragmatic randomized controlled trial of a quality improvement (QI) intervention of a prospective panel management intervention to optimize…
- Trial name
- DASH-HF (NCT05001165)
- Testing
- Proactive Panel Management Clinics for HFrEF
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Aging, Heart Failure With Preserved Ejection Fraction
Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure
In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage…
- Conditions
- Aging, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Frailty
- Trial name
- RETRO (NCT06576297)
- Testing
- Inspiratory Muscle Training (IMT), Standard of Care
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pittsburgh
Pediatric Heart Failure
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure
This study consists of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the way the body absorbs, distributes, metabolizes and removes the drug LCZ696.
- Trial name
- NCT02678312
- Testing
- LCZ696, Enalapril
- Where
- 98 sites in United States, Argentina and 27 more
- Volunteers
- 393 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure, Systolic
Hemodynamic-GUIDEd Management of Heart Failure
The GUIDE-HF IDE clinical trial is intended to demonstrate the effectiveness of the CardioMEMS™ HF System in an expanded patient population including heart failure (HF) patients outside of the present indication, but at risk for…
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II
- Trial name
- GUIDE-HF (NCT03387813)
- Testing
- CardioMEMS™ HF System
- Where
- 129 sites in United States, Canada
- Volunteers
- 2,358 people
- Sponsor
- Abbott Medical Devices
Heart Failure, Systolic, Heart Failure
A Multicenter Trial of a Shared DECision Support Intervention for Patients Offered Implantable Cardioverter-DEfibrillators
The investigators goal is to assess real-world effectiveness of patient decision aids (PtDA) for high-risk decisions using the implantable cardioverter-defibrillator (ICD) as a model.
- Trial name
- NCT03374891
- Testing
- Educational video and/or handout
- Where
- United States
- Volunteers
- 790 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Heart Failure
The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients
This is a phase IV, prospective, randomized, double-blind, double-dummy, parallel-group study. The study assessed the effects of 6 weeks of stable sacubitril/valsartan therapy, as compared with valsartan therapy, on the…
- Trial name
- TurkuPET (NCT03300427)
- Testing
- sacubitril/valsatran, valsartan
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systolic
Nicotinamide Riboside in Systolic Heart Failure
Mitochondrial dysfunction has been implicated in heart failure (HF), and is associated with an imbalance in intracellular ratio of reduced nicotinamide-adenine dinucleotide (NADH) to oxidized nicotinamide-adenine dinucleotide…
- Trial name
- NCT03423342
- Testing
- nicotinamide riboside
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Heart Failure, Decompensated Heart Failure
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
A randomized, double-blinded, placebo-controlled study of continuous 6-hour IV infusions of CXL-1427 in hospitalized patients with systolic heart failure.
- Conditions
- Heart Failure, Decompensated Heart Failure, Acute Heart Failure
- Trial name
- NCT02157506
- Testing
- CXL-1427
- Where
- 35 sites in United States, Germany and 3 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure, Systolic, Diabetes Mellitus, Type 2
Treatment of Diabetes in Patients With Systolic Heart Failure
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption [VO2]) and ventilator efficiency (minute ventilation…
- Trial name
- NCT02920918
- Testing
- Canagliflozin, Sitagliptin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Virginia Commonwealth University
Current or Recent History of Atrial Fibrillation
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
This study is being done to compare the effects of bucindolol hydrochloride (bucindolol) to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who…
- Trial name
- GENETIC-AF (NCT01970501)
- Testing
- bucindolol hydrochloride, metoprolol succinate
- Where
- 97 sites in United States, Canada and 4 more
- Volunteers
- 267 people
- Sponsor
- ARCA Biopharma, Inc.
Acute Heart Failure
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.
The purpose of this study was to assess the effect of in-hospital initiation of sacubitril/valsartan (LCZ696) vs. enalapril on time averaged proportional change in NT-proBNP in patients who have been stabilized following…
- Trial name
- PIONEER-HF (NCT02554890)
- Testing
- sacubitril/valsartan (LCZ696), Enalapril
- Where
- 123 sites in United States
- Volunteers
- 887 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
REALIsM-HF Pilot Study
The study aims to explore two marketed devices providing a multimarker monitoring including physical activity under real-life conditions in patients with heart failure with preserved ejection fraction (HFpEF) and with heart…
- Trial name
- REALIsM-HF (NCT03507439)
- Testing
- AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
- Where
- 5 sites in United States, Germany and 1 more
- Volunteers
- 27 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
- Trial name
- NCT03057977
- Testing
- Empagliflozin
- Where
- 520 sites in United States, Argentina and 18 more
- Volunteers
- 3,730 people
- Sponsor
- Boehringer Ingelheim
Chronic Heart Failure (CHF)
A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care
This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if…
- Trial name
- PREFER (NCT02807857)
- Testing
- Standard care
- Where
- 191 sites in Belgium, Croatia and 16 more
- Volunteers
- 1,415 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Diastolic
CoQ10 and D-ribose in Patients With Diastolic Heart Failure
The purpose of this study is to compare the clinical benefits of CoQ10 and D-ribose taken by patients who have diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF).
- Trial name
- NCT03133793
- Testing
- CoQ10, D-Ribose Oral Powder
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center